PD-L1 Assessment in Cytology Samples Predicts Treatment Response to Checkpoint Inhibitors in NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Lung Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC
Lung Cancer 2022 Jul 25;171(2022)42-46, SCM Lau, M Rabindranath, J Weiss, JJN Li, AS Fung, D Mullen, N Alshamlan, HM Ruff, LCB Tong, P Pal, MR Cabanero, YR Hsu, AG Sacher, FA Shepherd, G Liu, PA Bradbury, K Yasufuku, K Czarnecka-Kujawa, H Mi Ko, MS Tsao, NB Leighl, J SchwockFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.